The only accurate crypto trading system I know …

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

Robert A. Bradway net worth and biography

Robert Bradway Biography and Net Worth

Chairman & CEO of Amgen

Robert A. Bradway is Amgen’s chairman and chief executive officer. He became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company’s president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010.

Prior to joining Amgen, Bradway was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe. He joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990.

Bradway is a member of the board of directors of The Boeing Company, chairing its Finance committee and serving on its Governance and Public Policy committee. He also serves as a board member of the W. M. Keck Foundation and the Pharmaceutical Research and Manufacturers of America (PhRMA). In addition, Bradway serves on the board of trustees of the University of Southern California, he is an Emeritus Director of the CEO Roundtable on Cancer, and he is a member of the American Heart Association CEO Roundtable, which is helping the Association meet its goal of improving the cardiovascular health of all Americans.

Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University.

How old is Robert A. Bradway?: Mr. Bradway is currently 61 years old. There are 6 older executives and no younger executives at Amgen. The oldest executive at Amgen is Mr. Peter H. Griffith, Executive VP & CFO, who is 65 years old. Learn More on Robert A. Bradway's age.
How do I contact Robert A. Bradway?: The corporate mailing address for Mr. Bradway and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected]. Learn More on Robert A. Bradway's contact information.
Has Robert A. Bradway been buying or selling shares of Amgen?: Robert A. Bradway has not been actively trading shares of Amgen during the last quarter. Learn More on Robert A. Bradway's trading history.
Who are Amgen's active insiders?: Amgen's insider roster includes Robert Bradway (Chairman & CEO), Robert Eckert (Director), Murdo Gordon (EVP), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.
Are insiders buying or selling shares of Amgen?: During the last year, Amgen insiders bought shares 1 times. They purchased a total of 1,764,705 shares worth more than $29,999,985.00. During the last year, insiders at the medical research company sold shares 3 times. They sold a total of 21,654 shares worth more than $5,808,676.82. The most recent insider tranaction occured on December, 4th when SVP Nancy A Grygiel sold 2,096 shares worth more than $572,270.88. Insiders at Amgen own 0.5% of the company. Learn More about insider trades at Amgen.
Information on this page was last updated on 12/4/2023.

Robert A. Bradway Insider Trading History at Amgen

Robert A. Bradway Buying and Selling Activity at Amgen

Amgen Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $273.01

$269.65

$274.86

50 Day Range

MA: $275.77

$262.75

$289.18

2 Week Range

Now: $273.01

$211.71

$329.72

Volume

2,466,582 shs

Average Volume

2,840,533 shs

Market Capitalization

$146.44 billion

P/E Ratio

21.86

Dividend Yield

3.43%

Beta

0.58